Your session is about to expire
← Back to Search
Kinase Inhibitor
Sorafenib plus VT-122 for Hepatocellular Carcinoma
Phase 2
Waitlist Available
Research Sponsored by Vicus Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Summary
This trial is testing if VT-122, a combination of two drugs, can help patients with advanced liver cancer who have severe symptoms. The goal is to see if it can reduce inflammation and improve their ability to handle their main cancer treatment, possibly leading to better health and longer life.
Eligible Conditions
- Hepatocellular Carcinoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
failure free survival
Secondary outcome measures
clinical benefit response
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Sorafenib plus VT-122Experimental Treatment2 Interventions
Group II: Sorafenib with placeboPlacebo Group2 Interventions
Participants randomized to the Control Arm (sorafenib with placebo) receive sorafenib as the standard of care, and placebo for the same periods as participants randomized to the Treatment Arm (sorafenib plus VT-122). Participants randomized to the Control Arm will undergo the same visits and procedures as would the participants randomized to the Treatment Arm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sorafenib
FDA approved
Find a Location
Who is running the clinical trial?
Vicus TherapeuticsLead Sponsor
2 Previous Clinical Trials
72 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger